Peptides / Weight and metabolic

Synthetic analog · 34 amino acids · 4,563.1 Da

Mazdutide

Approved in ChinaNot banned in sport

Mazdutide is a weekly injection that acts on the GLP-1 and glucagon receptors, approved in China in 2025 for weight management and type 2 diabetes. Studies in people tested it for weight loss and blood sugar, and tracked stomach side effects. PepBank shows 161 results on mazdutide from 20 studies in people, and 25 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as IBI-362, IBI362, LY-3305677, LY3305677, Xinermei, 信尔美

34 amino acids, from first to last3 changed amino acids

Evidence level: Large trials in people161 of 186 results come from studies in people, including randomized trials.

Results in people

161

87% of 186 results

Results in animals

16

9% of 186 results

Results in lab cells

9

5% of 186 results

From computer models

0

0% of 186 results

Overview

Mazdutide at a glance

What it is	Synthetic analog, 34 amino acids
Approval	Approved in China only
In sport	Not listed as banned by WADA
Studies	28 studies with results. 23 of them gave mazdutide, with 186 results. 161 in people16 in animals9 in lab cells
Best study in people	Randomized controlled trial with 610 people (2025)
Clinical trials	45 registered: 25 active or planned, 1 with posted results
Community use	Weight loss (approved in China for chronic weight management)

The science

What is mazdutide?

Once-weekly injectable GLP-1 and glucagon receptor dual agonist peptide. Approved in China in 2025 for weight management and type 2 diabetes.

34

Amino acids in one chain

The history of mazdutide

2021
The oldest paper on mazdutide in PepBank is from 2021.
2022November
A registered trial of mazdutide started (NCT05607680).

Mazdutide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 34 amino acidsFrom the first amino acid to the last

H1XQGT5FTS−DY10S+KYL−D15−E+K+KA+K20−EFV−EW25LL−EGG30PSSG

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Mazdutide is a synthetic analog of 34 amino acids, with no ring, 3 changed amino acids.

Formula

C₂₁₀H₃₂₂N₄₆O₆₇

Molecular weight

4,563.1 g/mol

CAS number

2259884-03-0

Targets

Glucagon-like peptide 1 receptor (gene GLP1R): agonistEvidence: primary literatureGlucagon receptor (gene GCGR): agonistEvidence: primary literature

Development

Innovent Biologics (China, under license from Eli Lilly); Eli Lilly (outside China). Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL5095358, UNII MB76Z4IBZ5, DrugBank DB19099, KEGG D12225, IUPHAR 13924

Full sequence, SMILES and InChIKey

Three-letter sequence
H-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys[N6-(HOOC-(CH2)18-CO-gammaGlu-OEG-OEG)]-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2

See charge, composition and 3D structure on the Scientific page

The evidence

What mazdutide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people161 of 186 results come from studies in people, including randomized trials.

Weight and appetite

65 results · 65 in people

In Chinese adults with obesity or overweight, 4 mg weekly mazdutide led to more weight loss than placebo at week 32. The New England journal of medicine, 2025

Top results

Blood sugar

20 results · 20 in people

In Chinese adults with type 2 diabetes, mazdutide lowered HbA1c more than placebo after 20 weeks. Diabetes care, 2024

Top results

In Chinese adults with type 2 diabetes, mazdutide lowered HbA1c more than placebo after 20 weeks. (Diabetes care, 2024)
In Chinese adults with type 2 diabetes, mazdutide 4 mg lowered HbA1c more than placebo. (Nature, 2026)
In Chinese adults with type 2 diabetes, HbA1c fell from baseline after 12 weeks of IBI362 in all three dose cohorts. (Nature communications, 2022)

Cholesterol and blood fats

9 results · 7 in people · 1 animal · 1 lab

In pooled trials, mazdutide improved blood fat levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. Diabetes, obesity & metabolism, 2026

Top results

In pooled trials, mazdutide improved blood fat levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. (Diabetes, obesity & metabolism, 2026)
In mice with fatty liver, mazdutide improved fat handling compared with untreated mice. (Pharmaceuticals, 2026)
In a pooled analysis of trials, mazdutide lowered total cholesterol more than placebo. (Frontiers in endocrinology, 2024)

Heart and blood vessels

6 results · 6 in people

In a pooled analysis of trials, mazdutide lowered systolic blood pressure more than placebo. Frontiers in endocrinology, 2024

Top results

In a pooled analysis of trials, mazdutide lowered systolic blood pressure more than placebo. (Frontiers in endocrinology, 2024)
In Chinese adults with obesity or overweight, mazdutide showed benefits on all planned heart and metabolic measures. (The New England journal of medicine, 2025)
In adults with obesity and no diabetes, systolic blood pressure fell with mazdutide in pooled trials. (Diabetes, obesity & metabolism, 2026)

Liver

9 results · 1 in people · 6 animal · 2 lab

In pooled trials, mazdutide improved liver enzyme levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. Diabetes, obesity & metabolism, 2026

Top results

In pooled trials, mazdutide improved liver enzyme levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. (Diabetes, obesity & metabolism, 2026)
In mice fed a high-fat diet, mazdutide reduced liver fat more than semaglutide after 4 weeks. (Radiology, 2025)
In mice with fatty liver, mazdutide lowered liver injury markers compared with untreated mice. (Pharmaceuticals, 2026)

Metabolism and nutrition

1 result · 1 in people

In pooled trials, mazdutide improved uric acid levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. Diabetes, obesity & metabolism, 2026

Top results

In pooled trials, mazdutide improved uric acid levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments. (Diabetes, obesity & metabolism, 2026)

All 28 mazdutide studies by area Open the Scientific page

Key mazdutide studies

Studies in people come first, then studies in animals and in the lab.

People
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji et al. 2025 · The New England journal of medicine · 610 people · cited by 88
12 results
People
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
Gao et al. 2026 · JAMA · 461 people · cited by 0
6 results
People
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Zhu et al. 2026 · Nature · 320 people · cited by 11
11 results
People
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
Hsia et al. 2026 · The lancet. Diabetes & endocrinology · 179 people · cited by 0
7 results
People
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial
Ji et al. 2026 · Med (New York, N.Y.) · 80 people · cited by 3
6 results

All 28 Mazdutide studies

Mazdutide clinical trials

ClinicalTrials.gov lists 45 trials of mazdutide. 25 are active or planned, and 1 has posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Phase 3not yet recruiting912 planned

QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

Phase 4not yet recruiting820 planned

A Study of IBI362 in Participants With Type 2 Diabetes

Phase 3completed731 people

All 11 Mazdutide trials

Status and safety

Is mazdutide approved?

FDA

United States

Investigational

Investigational.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in China only. No FDA approval and no central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Mazdutide side effects and safety

PepBank has 62 safety results from studies of mazdutide. 62 of them come from studies in people.

Safety results from studies (62)

In Chinese adults with type 2 diabetes, IBI362 (mazdutide) was well tolerated over 12 weeks. (Nature communications, 2022)
In Chinese adults with overweight or obesity, no one stopped IBI362 (mazdutide) treatment because of safety concerns. (EClinicalMedicine, 2021)
In Chinese adults with overweight or obesity, no serious side effects were reported with mazdutide at these doses. (EClinicalMedicine, 2022)
In Chinese adults with overweight or obesity, no serious side effects were reported with IBI362 (mazdutide) at these doses. (Journal of the Endocrine Society, 2022)
In Chinese adults with type 2 diabetes, diarrhoea was one of the most common side effects of mazdutide. (Nature, 2026)
In Chinese adults with obesity or overweight, the most common side effects of mazdutide affected the stomach and bowel and were mostly mild to moderate. (The New England journal of medicine, 2025)
In Chinese adults with obesity, side effects made a few more people stop mazdutide 9 mg than placebo. (JAMA, 2026)
In Chinese adults with type 2 diabetes, diarrhoea was one of the most common side effects of mazdutide. (Nature, 2026)
In Chinese adults with obesity and no diabetes, nausea was more common with mazdutide 9 mg than with placebo. (Med, 2026)
In adults with overweight or obesity, no serious side effects were reported with mazdutide. (Diabetes, obesity & metabolism, 2025)
In Chinese adults with overweight or obesity, diarrhoea was a common side effect of mazdutide, which was well tolerated. (Nature communications, 2023)
In Chinese adults with type 2 diabetes, diarrhea was a common side effect of mazdutide. (Diabetes care, 2024)
In US adults with obesity or overweight, the most common side effects of mazdutide were stomach and gut problems, mostly mild to moderate. (The lancet. Diabetes & endocrinology, 2026)
In a pooled analysis of trials, mazdutide did not raise the rate of serious side effects. (Metabolism: clinical and experimental, 2024)
In pooled trials, stomach and gut side effects were more common with mazdutide than with the comparison treatments. (Diabetes, obesity & metabolism, 2026)
In a pooled analysis, mazdutide caused more mild or moderate stomach and bowel side effects than placebo. (Frontiers in endocrinology, 2024)
In adults with obesity and no diabetes, side effects were slightly more common with mazdutide in pooled trials. (Diabetes, obesity & metabolism, 2026)
In a pooled analysis of trials, mazdutide was the best tolerated of the agents compared. (Endocrinology, diabetes & metabolism, 2026)
In adults with overweight or obesity without diabetes, a pooled analysis suggested mazdutide was better tolerated, with low certainty and no clear comparator. (BMJ medicine, 2026)
In Chinese adults with overweight or obesity, no serious side effects were reported with IBI362 (mazdutide). (EClinicalMedicine, 2021)
In Chinese adults with overweight or obesity, all side effects during mazdutide treatment were mild or moderate. (EClinicalMedicine, 2022)
In Chinese adults with overweight or obesity, all side effects during IBI362 (mazdutide) treatment were mild or moderate. (Journal of the Endocrine Society, 2022)
In Chinese adults with type 2 diabetes, nausea was one of the most common side effects of mazdutide. (Nature, 2026)
In Chinese adults with type 2 diabetes, vomiting was one of the most common side effects of mazdutide. (Nature, 2026)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
4 mg once weekly	Human	human	Not reported	32 weeks	Randomized trial in people · n = 610	Ji 2025
6 mg once weekly	Human	human	Not reported	32 weeks	Randomized trial in people · n = 610	Ji 2025
9 mg	Human	human	subcutaneous	60 weeks	Randomized trial in people · n = 461	Gao 2026
3-6 mg, 10 mg and 16 mg	Human	human	subcutaneous	32 weeks	Randomized trial in people · n = 179	Hsia 2026
9 mg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 80	Ji 2026
4.5 mg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 63	Ji 2023
3 mg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 62	Ji 2023
6 mg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 61	Ji 2023
3.0 mg, 4.5 mg or 6.0 mg	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 42	Jiang 2022
3.0 mg, 4.5 mg or 6.0 mg	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 36	Ji 2021
9 mg and 10 mg cohorts	Human	human	subcutaneous	12 to 16 weeks	Randomized trial in people · n = 24	Ji 2022
9 mg and 10 mg cohorts	Human	human	subcutaneous	12 to 16 weeks	Randomized trial in people · n = 24	2022
3 mg, 4.5 mg or 6 mg	Human	human	subcutaneous	20 weeks	Randomized trial in people	Zhang 2024
4 mg	Human	human	subcutaneous	24 weeks	Randomized trial in people	Zhu 2026
6 mg	Human	human	subcutaneous	24 weeks	Randomized trial in people	Zhu 2026
3-6 mg	Human	human	subcutaneous	32 weeks	Randomized trial in people	Hsia 2026
10 mg	Human	human	subcutaneous	32 weeks	Randomized trial in people	Hsia 2026
16 mg	Human	human	subcutaneous	32 weeks	Randomized trial in people	Hsia 2026
9 mg (escalation 3 mg, 6 mg, 9 mg)	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 12	Ji 2022
10 mg (escalation 2.5 mg, 5 mg, 7.5 mg, 10 mg)	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 12	Ji 2022
9 mg (escalation 3 mg, 6 mg, 9 mg)	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 12	2022
10 mg (escalation 2.5 mg, 5 mg, 7.5 mg, 10 mg)	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 12	2022
4 mg and 6 mg	Human	human	Not reported	28 weeks	Randomized trial in people · n = 731	Guo 2026
4 mg or 6 mg once weekly	Human	human	Not reported	48 weeks	Randomized trial in people · n = 610	Ji 2025
4 mg and 6 mg	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 320	Zhu 2026
up to 16 mg once weekly	Human	human	subcutaneous	20 weeks	Randomized trial in people · n = 32	Bhattachar 2025
3.0 mg (escalation 1.0 mg, 2.0 mg, 3.0 mg)	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 12	Ji 2021
4.5 mg (escalation 1.5 mg, 3.0 mg, 4.5 mg)	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 12	Ji 2021
6.0 mg (escalation 2.0 mg, 4.0 mg, 6.0 mg)	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 12	Ji 2021
3 mg, 4.5 mg or 6 mg	Human	human	Not reported	24 weeks	Randomized trial in people	Ji 2023
10 mg cohort	Human	human	subcutaneous	16 weeks	Randomized trial in people	Ji 2022
4 mg	Human	human	Not reported	28 weeks	Randomized trial in people	Guo 2026
6 mg	Human	human	Not reported	28 weeks	Randomized trial in people	Guo 2026
10 mg cohort	Human	human	subcutaneous	16 weeks	Randomized trial in people	2022
3 mg	Human	human	Not reported	Not reported	Systematic review of studies	Kamrul-Hasan 2026
4 mg	Human	human	Not reported	Not reported	Systematic review of studies	Kamrul-Hasan 2026
6 mg	Human	human	Not reported	Not reported	Systematic review of studies	Kamrul-Hasan 2026
4 mg and 6 mg	Human	human	Not reported	Not reported	Systematic review of studies	Kamrul-Hasan 2026
4.5 mg or 6 mg	Human	human	Not reported	at least 16 weeks	Systematic review of studies · n = 15,584	Xie 2024
100, 200, or 400 μg/kg	Animal	mouse	subcutaneous	4 weeks	Study in live animals	Gan 2026

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Mazdutide is a glucagon and GLP-1 drug approved in China in 2025. Western community use is very limited. The one community source lists trial-based doses of 3 to 9 mg once a week.

Reported routines and cautions

What people use it for

Weight loss (approved in China for chronic weight management)S3S1

Reported regimens

Regimens that community sources report for Mazdutide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Copying the phase 3 trial doses (reported as niche)	subcutaneous injectionsupply mostly from Chinese research suppliers	3 to 9 mg per dose	once weekly	24 to 48 weeks	single source; the source carries seller links	S1

Cautions

Western access is very limited. Research-grade products from unregulated suppliers carry quality risks.S1
Trial data are mainly from Chinese people.S1

Status notes

News dated 2025-06-30 says China's NMPA approved mazdutide for chronic weight management in Chinese adults with overweight or obesity. The wiki says it is not approved in the US or EU.S3S1
News dated 2025-11-21 says mazdutide is approved in China for obesity at 4 mg and 6 mg, and that the maker plans to file for 9 mg. This is a news report, not the label. Later changes were not checked.S4
Per a law-firm summary, FDA issued warning letters on 2024-12-17 to five companies that offer GLP-1 products, including mazdutide. FDA determined that these products are unapproved new drugs.S2

Community sources

S1Mazdutide: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2FDA targets GLP-1 providers with warning letters (opens in a new tab)foley.com
S3China approves world's first dual GCG/GLP-1 receptor agonist for weight loss (opens in a new tab)biospectrumasia.com
S4Innovent boasts another pivotal trial success for obesity drug (opens in a new tab)clinicaltrialsarena.com

Gaps

Almost no community accounts were found. The only community source is a wiki that summarizes Reddit and lists trial doses, not verified user reports. No reported side effects from community users were found. The Chinese label could not be fetched, so no label regimen is recorded. The 4 mg and 6 mg approved doses come from a news report. Chinese-language forums were not searched.

Questions and more

Ask a question about mazdutide

The answer links to every study it uses.

What does the evidence say about mazdutide?Is mazdutide tested in people?Compare with Semaglutide Compare with Liraglutide

Sources

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about mazdutide

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).